About 7-methylguanosine phosphate-specific 5'-nucleotidase
7-methylguanosine phosphate-specific 5'-nucleotidase (NT5C3B) is a protein
from Homo sapiens identified by UniProt accession
Q969T7, 300 residues long.
MolForge cross-references it against 0 known binders and
11 disease associations.
Target properties
| Protein name | 7-methylguanosine phosphate-specific 5'-nucleotidase |
|---|
| UniProt accession | Q969T7 |
|---|
| Gene | NT5C3B |
|---|
| Organism | Homo sapiens |
|---|
| Length | 300 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (11)
Diseases linked to this target (Open Targets).
- appendicular lean mass · score 0.10
- reticulocyte count · score 0.08
- Immature Reticulocyte Fraction Measurement · score 0.08
- blood protein measurement · score 0.07
- reticulocyte measurement · score 0.06
- pulse pressure measurement · score 0.03
- mean corpuscular hemoglobin · score 0.02
- mean corpuscular volume · score 0.02
- Alzheimer disease · score 0.01
- acute lymphoblastic leukemia · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q969T7-F1 | alphafold | PREDICTED | 92.40 | — |
Amino-acid sequence (300 residues)
MAEEVSTLMK ATVLMRQPGR VQEIVGALRK GGGDRLQVIS DFDMTLSRFA YNGKRCPSSY NILDNSKIIS EECRKELTAL LHHYYPIEID PHRTVKEKLP HMVEWWTKAH NLLCQQKIQK FQIAQVVRES NAMLREGYKT FFNTLYHNNI PLFIFSAGIG DILEEIIRQM KVFHPNIHIV SNYMDFNEDG FLQGFKGQLI HTYNKNSSAC ENSGYFQQLE GKTNVILLGD SIGDLTMADG VPGVQNILKI GFLNDKVEER RERYMDSYDI VLEKDETLDV VNGLLQHILC QGVQLEMQGP
Explore 7-methylguanosine phosphate-specific 5'-nucleotidase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets